(Schedules of Concentration of Risk) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 25, 2020	Dec. 27, 2019
Distributor Concentration Risk | Revenue from Contract with Customer Benchmark [Member] | CuraScript, Inc [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	26.10%	27.40%	29.70%
Distributor Concentration Risk | Revenue from Contract with Customer Benchmark [Member] | Amerisource Bergen Corporation [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			10.20%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | CuraScript, Inc [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	12.70%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | McKesson Corporation [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	15.00%	18.20%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | Amerisource Bergen Corporation [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	30.00%	33.60%
Product Concentration Risk | Net Sales Attributable to Products | Acthar Gel (1)
Concentration Risk [Line Items]
Concentration risk, percentage	26.90%	27.90%	30.10%
Product Concentration Risk | Net Sales Attributable to Products | Inomax
Concentration Risk [Line Items]
Concentration risk, percentage	20.30%	20.90%	18.10%
Product Concentration Risk | Net Sales Attributable to Products | Ofirmev [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		10.10%	12.10%
Product Concentration Risk | Net Sales Attributable to Products | Therakos
Concentration Risk [Line Items]
Concentration risk, percentage	12.10%